TY - GEN
AU - Parry, Helen
AU - Bruton, Rachel
AU - Roberts, Thomas
AU - McIlroy, Graham
AU - Damery, Sarah
AU - Sylla, Panagiota
AU - Dowell, Alexander C.
AU - Tut, Gokhan
AU - Lancaster, Tara
AU - Bone, David
AU - Willett, Brian J.
AU - Logan, Nicola
AU - Scott, Sam
AU - Hulme, Sam
AU - Jadir, Azar
AU - Amin, Umayr
AU - Nicol, Sam
AU - Stephens, Christine
AU - Faustini, Sian
AU - Al-Taei, Saly
AU - Richter, Alex
AU - Blakeway, Daniel
AU - Verma, Kriti
AU - Margielewska-Davies, Sandra
AU - Pearce, Hayden
AU - Pratt, Guy
AU - Zuo, Jianmin
AU - Paneesha, Shankara
AU - Moss, Paul
PY - 2022
DA - May
TI - COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
EP - 586
VL - 40
IS - 6
DO - http://dx.doi.org/10.1016/j.ccell.2022.05.001
AB - B cell chronic lymphocytic leukemia (CLL) is the most common subtype of adult leukemia and is associated with profound secondary immunodeficiency. SARSCoV-2 infection has been a significant cause of morbidity and mortality (Mato et al., 2020; Pagano et al., 2021), and immunological responses against SARSCoV-2 vaccines are impaired (Fendler et al., 2021) in patients with CLL. In particular, reduced rates of seroconversion and antibody titer have been reported (Parry et al., 2021; Greenberger et al., 2021; Herishanu et al., 2022) and associate with reduced serum immunoglobulin level or use of medication such as Bruton tyrosine kinase inhibitors or anti-CD20 antibodies (Parry et al., 2021; Herishanu et al., 2022). However, questions regarding optimal immune protection remain  unresolved, and these include the potential for additional vaccine doses to increase seroconversion rate, potential humoral and cellular immune protection against Omicron, and the impact of vaccine delivery on breakthrough infection rate and clinical outcome.
PB - Elsevier
UR - http://eprints.gla.ac.uk/272397/
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER